Sana Biotechnology (NASDAQ:SANA) Trading Down 4%

Sana Biotechnology, Inc. (NASDAQ:SANA) shares were down 4% during mid-day trading on Monday . The stock traded as low as $9.96 and last traded at $10.02. Approximately 710,317 shares were traded during mid-day trading, a decline of 76% from the average daily volume of 2,934,561 shares. The stock had previously closed at $10.44.

Analyst Ratings Changes

Several analysts recently issued reports on SANA shares. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Sana Biotechnology in a report on Friday, March 1st. JMP Securities increased their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “market outperform” rating in a report on Friday, March 1st.

Sana Biotechnology Price Performance

The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of -6.40 and a beta of 1.62. The stock’s fifty day simple moving average is $9.23 and its two-hundred day simple moving average is $6.46.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.03. During the same quarter in the prior year, the business posted ($0.40) EPS. On average, sell-side analysts predict that Sana Biotechnology, Inc. will post -1.06 EPS for the current year.

Insider Transactions at Sana Biotechnology

In other news, Director Robert Nelsen purchased 1,818,181 shares of the stock in a transaction dated Thursday, February 8th. The stock was acquired at an average price of $5.50 per share, for a total transaction of $9,999,995.50. Following the completion of the transaction, the director now owns 12,446,022 shares of the company’s stock, valued at $68,453,121. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 34.90% of the company’s stock.

Hedge Funds Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of SANA. TD Asset Management Inc grew its position in Sana Biotechnology by 100.0% in the 3rd quarter. TD Asset Management Inc now owns 362,652 shares of the company’s stock valued at $1,403,000 after buying an additional 181,326 shares in the last quarter. State of Michigan Retirement System bought a new position in shares of Sana Biotechnology during the 3rd quarter valued at about $2,663,000. Principal Financial Group Inc. boosted its position in shares of Sana Biotechnology by 13.1% during the 3rd quarter. Principal Financial Group Inc. now owns 42,664 shares of the company’s stock valued at $165,000 after purchasing an additional 4,928 shares in the last quarter. Jump Financial LLC bought a new position in shares of Sana Biotechnology during the 3rd quarter valued at about $52,000. Finally, Barclays PLC boosted its position in shares of Sana Biotechnology by 3.1% during the 3rd quarter. Barclays PLC now owns 205,567 shares of the company’s stock valued at $797,000 after purchasing an additional 6,096 shares in the last quarter. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.